Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?


Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.

Aim(s): a) to confirm this data in a larger population, b) to compare its efficacy with alkylating agents, c) to explore if O6-methylguanine-DNA methyltransferase (MGMT) status could help to choose between both types of chemotherapies.

Materials and methods: 96 patients with metastatic NET were treated with gemox (2004-2014), after a median of 2 other systemic treatments. Among these 96 patients, 57 also received an alkylating agent (ALK). Promoter gene methylation of MGMT was assessed by pyrosequencing in 23 patients treated with both chemotherapies.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Dussol A, Joly M, Hervieu V, Forestier J, Lombard-Bohas C,

Keywords: gemox, alkylating agent, MGMT,

To read the full abstract, please log into your ENETS Member account.